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The purpose of this study was to investigate the clinicopathological and biological significance of human carcinoembryonic antigen-
related cell adhesion molecule 6 (CEACAM6) gene expression in human intrahepatic cholangiocarcinoma. CEACAM6 is reported to
be involved in human malignancies. However, in cholangiocarcinoma expression of CEACAM6 and its clinicopathological significance
have not been investigated. CEACAM6 expression status was determined and analysed with respect to various clinicopathological
parameters in 23 intrahepatic cholangiocarcinomas. Additionally, we investigated effects of CEACAM6 gene in the cholangiocarcinoma
cell lines. CEACAM6 gene expression in cancer tissues was higher than in noncancerous tissues in 16 of the 23 cases; however, it was
not statistically significant. The tumours with elevated CEACAM6 expression showed a tendency to be associated with lymphatic
invasion and stage of the disease. Interestingly, patients with high CEACAM6 expression showed a significantly poorer disease-free
survival rate than those with low CEACAM6 expression. We demonstrated that CEACAM6-transfected cells were more proliferative,
more invasive and more chemoresistant to gemcitabine compared to mock-transfected cells. Furthermore, CEACAM6 gene silencing
by CEACAM6-specific siRNA resulted in higher chemosensitivity to gemcitabine. CEACAM6 is a potential prognostic indicator and
potential chemoresistant marker to gemcitabine for patients with intrahepatic cholangiocarcinoma.
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Cholangiocarcinoma is a malignant neoplasm arising from the
biliary epithelium, either within the liver (intrahepatic cholangio-
carcinoma) or extrahepatic bile duct (extrahepatic cholangiocarci-
noma). Although it is a relatively rare malignancy, the worldwide
incidence of intrahepatic cholangiocarcinoma is steadily increas-
ing (Olnes and Erlich, 2004; Khan et al, 2005; Lazaridis and Gores,
2005). The overall survival rate is poor; o5% of patients survive
more than 5 years, and the rate has not changed significantly over
the past 30 years (Shaib and El-Serag, 2004). The curative
treatment of cholangiocarcinoma is surgical resection. More than
two-thirds of patients with cholangiocarcinoma are not resectable
at the time of initial diagnosis (Khan et al, 2002), because it is
clinically silent until it has become an advanced disease with
obstructive symptoms. Chemotherapy for cholangiocarcinoma is
carried out for those patients who are inoperable or who have
recurrent disease, but the results tend to be disappointing (Olnes
and Erlich, 2004; Khan et al, 2005). Several different new
anticancer drugs are under investigation for the treatment of
advanced cholangiocarcinoma (Thongprasert, 2005). Among
those, one agent – the nucleoside analog gemcitabine – was
reported to show efficacy in treating advanced cholangiocarcinoma
(Thongprasert, 2005).
Carcinoembryonic antigen-related cell adhesion molecule 6
(CEACAM6) is a glycosylphosphatidylinositol(GPI)-linked immuno-
globulin super family member (Thompson et al, 1991) that is
overexpressed in a variety of malignancies (Hasegawa et al, 1993;
Kodera et al, 1993; Jantscheff et al, 2003; Duxbury et al, 2004a).
Despite lacking an intracellular domain, CEACAM6 is able to
influence intracellular signaling events, and overexpression of this
molecule appears to promote gastrointestinal cancer progression
(Scholzel et al, 2000; Ilantzis et al, 2002). Silencing of the
CEACAM6 gene impairs metastasis and suppresses tumor growth
(Duxbury et al, 2004a,b). In cholangiocarcinoma, CEACAM6
expression and its relation to clinicopathological factors have not
been investigated.
In the present study, we investigated the expression of
CEACAM6 in patients with intrahepatic cholangiocarcinoma
using real-time quantitative reverse transcription–polymerase
chain reaction (RT-PCR) to analyse the association of
clinicopathological factors and prognosis with CEACAM6
expression levels. Furthermore, we established a CEACAM6
stably transfected human cholangiocarcinoma cell line and
examined the biological behaviour of CEACAM6-transfected cells,
such as cell growth, invasiveness, resistance to anoikis and
gemcitabine chemosensitivity. We also examined whether silen-
cing the CEACAM6 gene by siRNA enhanced gemcitabine
chemosensitivity.
MATERIALS AND METHODS
Cell lines
The human cholangiocarcinoma cell lines, TFK-1, HuCC-T1 and
MEC were provided by the Cell Resource Center of Biomedical
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sResearch, Institute of Development, Aging and Cancer (Tohoku
University, Sendai, Japan) and maintained in RPMI 1640 medium
containing 10% fetal bovine serum (FBS) and antibiotics at 371Ci n
a 5% humidified CO2 atmosphere.
Clinical samples
Patients (23) with intrahepatic cholangiocarcinoma who under-
went surgery at the Medical Institute of Bioregulation Hospital and
the Department of Surgery and Science, Kyusyu University
between 1993 and 2002 were enrolled in this study. All patients
underwent a resection of the primary cancer. No patients received
chemotherapy or radiotherapy prior to or after operation. The
resected cancer (T) and paired noncancerous (N) tissue specimens
were immediately frozen in liquid nitrogen and kept at  801C until
the extraction of RNA. Written informed consent was obtained
from all patients. The follow-up ranged from 1 to 74 months with a
median of 12 months.
Oligonucleotide primers for CEACAM6 gene amplification
by RT–PCR
Total RNA was extracted from each sample and complementary
DNA (cDNA) was synthesized from 8mg of total RNA using
random hexamer primers and M-MLV reverse transcriptase
(Invitrogen Crop., Carlsbad, CA, USA) as described previously
(Mori et al, 2002).
The oligoribonucleotide primers for CEACAM6 (226bp) were
sense primer: 50-GAAATACAGAACCCAGCGAGTGC-30; antisense
primer: 50-CAGTGATGTTGGGGATAAAGAGC-30, glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (270bp) sense primer: 50-
TTGGTATCGTGGAAGGACTCA-30; antisense primer: 50-TGTCA
TCATATTTGGCAGGTT-30. To avoid amplification of contaminat-
ing genomic DNA, these primers spanned more than two exons.
The amplification was performed for 30 cycles of 1min at 951C,
1min at 691C and 1min at 721C. An 8ml aliquot of each PCR-
amplified DNA was electrophoresed on a 2% agarose gel contain-
ing ethidium bromide. To ensure that the RNA was of sufficient
purity for RT–PCR, a PCR assay with primers specific for the
GAPDH gene was carried out in each case, except that only 22
cycles were performed under the following cycling conditions:
1min at 951C, 1min at 561C and 1min at 721C.
Real-time quantitative RT–PCR
The PCR amplification for quantification of CEACAM6 and
GAPDH mRNA in clinical samples was performed in the
LightCycler system (Roche Applied Science, IN, USA) using the
LightCycler-FastStart DNA Master SYBR Green I kit (Roche
Applied Science, IN, USA) as described previously (Ogawa et al,
2005). The amplification conditions of cycles consisted of initial
denaturation at 951C for 10min, followed by 40 cycles of
denaturation at 951C for 10s, annealing at 721C (601C for GAPDH)
for 10s, and elongation at 721C for 10s. For distinguishing specific
from nonspecific products and primer dimers, melting curve
analysis was carried out. To verify the melting curve results, each
representative sample of the PCR products was electrophoresed on
2% agarose gels, and a single PCR product of the size predicted
from the cDNA was confirmed. To quantitate the amount of
specific mRNA in the samples, a standard curve was produced for
each run measuring three points of the diluted TFK-1 cDNA. The
concentrations of each sample were calculated by observing their
crossing point to a standard curve. The relative expression levels of
CEACAM6 were obtained by normalizing the amount of CEACAM6
mRNA divided by that of GAPDH mRNA as an endogenous control
in each sample. Each assay was performed at least twice to verify
the results, and the mean mRNA expression was used for analysis.
Immunohistochemistry
Immunohistochemical studies of CEACAM6 were performed on
surgical specimens from intrahepatic cholangiocarcinoma patients
on formalin-fixed, paraffin-embedded tissues. After deparaffiniza-
tion and blocking, the antigen–antibody reaction was incubated
overnight at 41C. ENVISION reagents (ENVISIONþ Dual Link/
HRP, Dako Cytomation, Denmark) were applied to detect the
signal of the antigen-antibody reaction. All sections were counter-
stained with haematoxylin. The primary mouse monoclonal
antibodies against CEACAM6 (GM7G5, Alexis Biochemicals,
USA) were used at dilution of 1:100.
Flow cytometry analysis
The cells were harvested and rinsed twice with PBS. Dissociated
cells were stained with PE-conjugated anti-CEACAM6 antibody
(KOR-SA3544 antigen-PE, Beckman Coulter, USA) and incubated
for 30min at room temperature. Cells (10000) were collected for
each sample using FACScan, and the data were analysed with
CellQuest software (Becton Dikinson, San Jose, CA, USA).
Cytotoxic assay
Cytotoxicity was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyl tetrazolium bromide (MTT) assay (Roche Diagnostics
Corp., GmbH). Logarithmically growing cells were seeded at
3–5 10
3cellswell
 1 in microtitre plate wells (96 wells, flat
bottom) in a final volume of 100ml culture medium per well, in
a humidified atmosphere (371C and 5% CO2). The cells were
cultured overnight for adherence and gemcitabine was added at a
concentration of 0–1mgml
 1 into the plates. Gemcitabine-
induced cytotoxicity was determined after 48–72h of exposure.
After incubation, 10ml of MTT labelling reagent (final concentra-
tion 0.5mgml
 1) was added to each well. The microtitre plate
was incubated for 4h in a humidified atmosphere. Solubilisation
solution (100ml) was added to each well. The plate was
allowed to stand overnight in the incubator in a humidified
atmosphere. After checking for complete solubilisation of the
purple formazan crystals, the spectrophotometrical absorbance of
the samples was measured using a model 550 microplate reader
(Bio-Rad Laboratories, CA, USA), at a wavelength of 570nm
corrected to 655nm. Each independent experiment was performed
three times.
Transfection assays and establishment of a stable
CEACAM6-transfected cholangiocarcinoma cell line
Human CEACAM6 cDNA was generated by RT–PCR and sub-
cloned into pcDNA3.1/Hygro
r (þ) expression vector (Invitrogen
Corp., Carlsbad, CA, USA) according to the manufacturer’s
protocol. To confirm accurate insertion into the frame of the
expression vector, sequencing chemistry were performed. Trans-
fection into the cholangiocarcinoma cell line (HuCC-T1) was
performed by the Lipofectaminet2000 method (Invitrogen Crop.,
Carlsbad, CA, USA) as described previously (Shibata et al, 1999).
Then, stable transfected clone expressing abundant CEACAM6
protein were selected after hygromicine B (600mgml
 1) (Invitro-
gen Crop., Carlsbad, CA, USA) treatment and used for the
subsequent experiments. A mock vector-transfected clone was
used for control.
In vitro proliferation assay
MTT assay Logarithmically growing cells were seeded at
5 10
3cellswell
 1 in microtiter plate wells (96 wells, flat bottom)
in a final volume of 100ml culture medium per well. After 0–96h
culture, spectrophotometrical absorbance of the samples was
CEACAM6 expression in cholangiocarcinoma
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performed three times.
ELISA analysis ELISA was performed using the BrdU ELISA kit
(Roche Diagnostic Corp., Tokyo, Japan). Logarithmically growing
cells were seeded at 1 10
4cellswell
 1 in microtitre plate wells (96
wells, flat bottom) in a final volume of 100ml culture medium per
well. After overnight culture, BrdU was added to a concentration of
10mM into each well and incubated for 5h. Cells were fixed by
FixDenat and anti-BrdU-POD reaction liquid was added. The
spectrophotometrical absorbance of the samples was measured
using a model 550 microplate reader (Bio-Rad Laboratories, CA,
USA), at a wavelength of 450nm. Each independent experiment
was performed three times.
Cell cycle analysis
Cells (1.0 10
6) were preincubated for 48h or 72h in serum-free
medium at 371C and then were kept in medium with serum (10%
FBS) for 18h at 371C. The cells were harvested and fixed in 70%
ethanol at  201C. Then, the cells were washed and resuspended in
propidium iodide (PI) staining buffer (5mgml
 1 PI and 0.25mgml
 1
RNase) in PBS. DNA content was evaluated using an EPICS XL flow
cytometer (Beckman Coulter Corp., Tokyo, Japan).
In vitro invasion assay
In vitro invasion assays were performed using the BD BioCoatt
Tumor Invasion System (Becton Dickinson, San Jose, CA, USA) to
evaluate invasive cells as described previously (Albini et al, 1987).
Cells (5.0 10
4cellswell
 1) were placed in the upper chamber, and
the lower chamber was filled with 750ml of RPMI1640 with 10%
FBS as a chemoattractant. After 48h and 72h of incubation at
371C, the membranes were labelled with Calcein-AM solutions.
The invasive cells that had migrated through the membrane to the
lower surface were read in a fluorescence plate reader at excitation/
emission wavelengths of 485/530nm using Multilabel Plate
Counters VICTOR3 (PerkinElmer, Inc., USA).
Anoikis assay
Anoikis was induced by poly (2-hydroxyethyl methacrylate) (poly-
H E M A ,S i g m a )c u l t u r e .As o l u t i o no f1 2 0 m g m l
 1 poly-HEMA in
100% ethanol was made and diluted 1:10 in 95% ethanol. Of this
solution 0.95ml was pipetted into 35mm wells and left to dry for 48h
at room temperature. Prior to use, the wells were washed twice with
PBS and once with RPMI-1640. Cells (1 10
6), suspended in 2ml of
RPMI-1640 with 10% FBS, were incubated in the poly-HEMA-coated
wells for 18h in a humidified (371C, 5% CO2) incubator. Following
the induction of anoikis, the cells were washed and resuspended in
0.5ml of binding buffer, and annexin V/fluorescein isothiocyanate/
propidium iodide labelling was performed in accordance with the
manufacturer’s protocol (BD biosciences). Analysis was performed
by FACScan. A total of 10000 cells were collected for each sample,
and the data were analysed with CellQuest software (Becton
Dickinson, San Jose, CA, USA).
CEACAM6 RNA interference
CEACAM6-specific siRNA (Silencert Predesigned siRNA; sense:
GGAGGUUCUUCUACUCGCCtt, antisense: GGCGAGUAGA
AGAACCUCCtt) and negative control siRNA (Silencert Negative
Control siRNA) were purchased from Ambion, USA. Logarith-
mically growing cells (TFK-1) were seeded at either 1.5 10
5 or
3 10
3cellswell
 1 in a final volume of 2ml or 100ml in six- or 96-
well flat-bottom microtitre plates, respectively. The cells were
cultured overnight for adherence. siRNA oligomer was diluted with
Opti-MEN
s I Reduced Sereum Medium (Invitrogen Corp.,
Carlsbad, CA, USA) and incubated for 5min at room temperature.
The diluted siRNA oligomer was mixed with the diluted
Lipofectaminet2000 and incubated for 20min at room tempera-
ture to allow siRNA-Lipofectaminet2000 complexes to form. The
siRNA-Lipofectaminet2000 complexes were added to each well to
a final concentration of 50pmolml
 1. The cells were incubated in
humidified atmosphere (371C and 5% CO2) and the growth
medium was replaced after 4h. The assay was performed after 48h
incubation.
Statistical analysis
For continuous variables, the data were expressed as the means
7standard deviation (s.d.). The relationship between the CEA-
CAM6 expression and clinicopathological factors and in vitro assay
data were analysed using the Student’s t test, the Wilcoxon/
Kruskal–Wallis test, w
2 test, and Repeated Measures ANOVA
analysis. Overall survival curves and disease-free survival curves
were plotted according to the Kaplan–Meier method measured
from the day of surgery, and the generalised Wilcoxon test and the
log-rank test were applied for comparison. All differences were
deemed significant at the level of Po0.05. Statistical analysis was
performed with the JMP software package (SAS Institute Inc., Cary,
NC, USA).
RESULTS
Clinical study
Expression of CEACAM6 mRNA in cell lines and clinical tissue
specimens Expression of CEACAM6 mRNA in cell lines was
shown by RT–PCR. TFK-1 cells showed a higher expression level
of CEACAM6 mRNA than that of HuCC-T1 and MEC cells. The
expression of CEACAM6 mRNA in cancer and noncancerous
tissues of the patients with intrahepatic cholangiocarcinoma was
examined by RT–PCR and real-time PCR. The expression levels of
CEACAM6 mRNA, which were corrected for those of GAPDH
mRNA, in cancer tissues (5.9078.74; mean7s.d.) were higher
than in noncancerous tissues (0.7070.48; mean7s.d.) in 16 of the
23 cases (69.6%). No differences in mRNA mean expression level
was found between cancer and noncancerous tissues statistically
(P¼0.10: the Wilcoxon/Kruskal–Wallis test) (Figure 1A and B).
The cases with values of CEACAM6 under 2 in cancer tissues were
considered to be a low expression group (n¼13), whereas those
with values 2 or over were considered to be a high expression
group (n¼10). The clinical implications of CEACAM6 in patients
with intrahepatic cholangiocarcinoma were evaluated by compar-
isons between these two groups.
The clinicopathological significance of CEACAM6 mRNA
expression in intrahepatic cholangiocarcinoma
The clinicopathological features analysed in relation to the
CEACAM6 expression status are given in Table 1. The clinico-
pathological factors showed a tendency that the high expression
group (seven of 10, 70.0% lymphatic invasion) showed more
invasiveness of lymph nodes compared to the low expression
group (four of 13, 30.8% lymphatic invasion) (P¼0.06). The high
expression group (six of 10, 60.0% stage 4) was also at a later
progression stage of disease than the low expression group (three
of 13, 23.0% stage 4) (P¼0.09). On the other hand, no significant
differences were observed regarding age, gender, tumour size,
lymph node metastasis, vascular invasion, perineural invasion or
histology. In the disease-free survival curve, patients in the high
expression group had a significantly poorer prognosis than those
in the low expression group, as illustrated in Figure 1C (Po0.05;
Wilcoxon test, log-rank test). The overall survival rate between the
CEACAM6 expression in cholangiocarcinoma
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(data not shown).
Immunohistochemical staining
Staining of CEACAM6 was markedly stronger in cancer tissue than
corresponding noncancerous hepatic tissue. Expression of CEA-
CAM6 was localized to the cell membrane (Figure 2). The
immunohistochemical results closely corresponded with the
RT–PCR.
Experimental study
Chemosensitivity of gemcitabine in cholangiocarcinoma cell
lines Flow cytometry analysis of expression levels of the
CEACAM6 protein in cholangiocarcinoma cell lines showed that
TFK-1 cells had higher expression levels of the CEACAM6 protein
than the other two cell lines (HuCC-T1, MEC) (Figure 3A). The
expression levels of CEACAM6 protein was correlated with that of
mRNA. We analysed the relation between CEACAM6 expression
and gemcitabine sensitivity in cholangiocarcinoma cell lines. MTT
assays for sensitivity of gemcitabine showed TFK-1 cells were more
resistant than HuCC-T1 and MEC cells (Po0.01: Repeated
Measures ANOVA analysis) (Figure 3B). TFK-1 cells that highly
expressed CEACAM6 were more resistant to gemcitabine than
other cell lines.
The effect of CEACAM6 gene transfected into the
cholangiocarcinoma cell line
HuCC-T1 cells showed a low expression level of CEACAM6. Stable
CEACAM6 overexpressing clones were established using the
pcDNA3.1/hygro
r (þ) expression vector. Overexpression of
CEACAM6 was confirmed with RT–PCR and flow cytometry
(Figure 4A).
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Figure 1 (A) Expression of CEACAM6 by RT–PCR in representative intrahepatic cholangiocarcinoma patient tissues (T: cancer tissue, N: noncancerous
tissue, n: negative control, p: positive control, m: indicates marker). (B) CEACAM6 mRNA expression in cancer and noncancerous tissue with intrahepatic
cholangiocarcinoma patients by real-time PCR (n¼23). Horizontal lines indicate means. (C) Kaplan–Meier disease-free survival curves in patients with
intrahepatic cholangiocarcinoma according to the level of CEACAM6 mRNA expression. The recurrence rate for patients in the high expression group was
significantly higher than that for patients in the low expression group (Po0.05). High expression group (n¼10): CEACAM6/GAPDH X2, Low expression
group (n¼13): CEACAM6/GAPDH o2.
Table 1 CEACAM6 gene expression and the clinicopathological features
of twenty-three patients with intrahepatic cholangiocarcinoma
CEACAM6/GAPDH
High expression group Low expression group
X2( n¼10) o2( n¼13) P-value
Age 64.073.9 61.373.5 0.61
Gender
Male 7 10 0.54
Female 3 3
Tumour size 6.370.7 5.170.6 0.21
Lymph node metastasis
Absent 5 10 0.18
Present 5 3
Lymphatic invasion
Absent 3 9 0.06
Present 7 4
Vascular invasion
Absent 2 4 0.46
Present 8 9
Perineural invasion
Absent 4 9 0.16
Present 6 4
Histology
Moderate 8 6 0.11
Poor 2 7
Stage
1, 2, 3 4 10 0.09
46 3
CEACAM6 expression in cholangiocarcinoma
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Figure 2 Immunohistochemistry with CEACAM6 antibody in intrahepatic cholangiocarcinoma. The majority of stain was observed in cancer cells. (A)
original magnification  40, haematoxylin and eosin stain, (B) original magnification  40, CEACAM6 stain, (C) original magnification  100, haematoxylin
and eosin stain, (D) original magnification  100, CEACAM6 stain, T: cancer tissue, N: noncancerous tissue.
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Figure 3 (A) Expression of CEACAM6 in three cholangiocarcinoma cell lines (TFK-1, HuCC-T1, MEC) by flow cytometry. TFK-1 cells showed higher
expression of CEACAM6 than HuCC-T1 and MEC. (B) Gemcitabine chemosensitivity of cholangiocellular carcinoma cell lines. After 48h gemcitabine
exposure, survival rates of each cells were measured by MTT assay. TFK-1 cells were more chemoresistant than HuCC-T1 and MEC (Po0.01). The data
represent the mean7s.d.
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the growth rate of HuCC-T1 cholangiocarcinoma cells. As shown
in Figure 4B and 4C, there was a significant difference in growth
rate between the CEACAM6 overexpressing cells and the mock-
transfected cells (MTT assay: Po0.01; Repeated Measures ANOVA
analysis, ELISA analysis: Po0.01; Student’s t test). In cell cycle
analysis, after 48h serum starvation and 18h incubation with
serum, a greater percentage of CEACAM6 overexpressing cells
(73.1% S phase) were in S phase than mock-transfected cells
(63.4% S phase) (Figure 4D). After 72h serum starvation, the same
pattern was identified.
In the clinicopathological studies, we found a tendency that the
incidence of lymphatic invasion was higher in the CEACAM6 high
expression group than in the CEACAM6 low expression group
(Table 1). To verify these findings in an in vitro assay, we
examined the invasive potential of the CEACAM6 overexpressing
cells using an in vitro matrigel invasion assay. Invasion assay
showed that CEACAM6 overexpressing cells were more signifi-
cantly invasive than mock-transfected cells (Po0.01: the Wilcoxon/
Kruskal–Wallis test) (Figure 5A). High expression of CEACAM6
enhanced tumour invasiveness.
Anoikis is associated with cellular invasion and metastatic
potential. After anoikis-induced culture, mock-transfected cells
(16.7%) were more apoptotic than CEACAM6 overexpressing cells
(10.6%). CEACAM6 overexpressing cells were more resistant to
anoikis than mock-transfected cells (Figure 5B).
We examined whether CEACAM6 expression in cholangiocarci-
noma cell line (HuCC-T1) would alter sensitivity to gemcitabine.
We compared CEACAM6 overexpressing cells and mock-
transfected cells. Overexpression of CEACAM6 induced chemo-
resistance to gemcitabine which was significantly increased as
observed by the MTT assay (Po0.01: Repeated Measures ANOVA
analysis) (Figure 5C).
The effect of CEACAM6 gene silencing on gemcitabine
chemosensitivity
TFK-1 cells showed a high expression level of CEACAM6
and strong chemoresistance to gemcitabine. We examined
whether suppression of CEACAM6 expression would alter
sensitivity to gemcitabine. The expression level of mRNA
and protein was suppressed by CEACAM6-specific siRNA as
confirmed by RT–PCR and flow cytometry analysis (Figure 6A).
Suppression of CEACAM6 expression reduced chemoresistance to
gemcitabine (Po0.01: Repeated Measures ANOVA analysis)
(Figure 6B).
DISCUSSION
CEACAM6 is highly expressed in various human cancer tissues
and its clinical significance has been widely reported (Hasegawa
et al, 1993; Kodera et al, 1993; Scholzel et al, 2000; Ilantzis et al,
2002; Jantscheff et al, 2003; Duxbury et al, 2004a). CEACAM6
overexpression independently predicts poor overall and disease-
free survival, and correlates inversely with cellular differentiation
in colorectal cancer (Ilantzis et al, 2002; Jantscheff et al, 2003).
Duxbury et al (2005) showed that CEACAM6 expression was
associated with adverse pathologic features and prognosis in
pancreatic cancer. In gastric cancer, CEACAM6 was overexpressed;
however, there was no significant association between the
expression level and clinicopathological features (Yasui et al,
2004). This study of intrahepatic cholangiocarcinoma indicates
that higher expression of CEACAM6 correlated with lymph node
invasion (P¼0.06), advanced stage of the disease (P¼0.09), and
poorer prognosis (Po0.05). Thus, its association between
CEACAM6 expression and poor prognosis in intrahepatic
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Figure 4 (A) CEACAM6 Expression of transfectants and mock cells (HuCC-T1). Expression levels of CEACAM6 protein were markedly increased in
transfectants. (B) MTT assay. CEACAM6-transfectants were more proliferative than mock cells (Po0.01). The data represent the mean7s.d. (C)
Comparison of BrdU uptake. The average BrdU uptake of transfectants was increased compared with mock cells. The data represent the mean7s.d. (D)
Cell cycle analysis of transfectants and mock cells. After 48h starvation and 18h incubation with serum, transfectants (73.1%) were more in S phase than
mock cells (63.4%).
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pancreatic cancer.
The reason why CEACAM6 overexpression is associated with
aggressive biological behaviour of cancer cells has not been fully
clarified. However, to date several possibilities have been
considered. Overexpression of CEACAM6 is associated with
greater resistance to anoikis (Ordonez et al, 2000; Ilantzis et al,
2002), a subset of apoptosis induced by inadequate or inappropri-
ate cell substrate adhesion, and increased Akt and c-Src kinase
activities (Duxbury et al, 2004a). Resistance to anoikis is a
property of transformed cells that is associated with greater
cellular invasive ability and in vivo metastatic potential (Yawata
et al, 1998; Shanmugathasan and Jothy, 2000). Wandering
CEACAM6 overexpressed cells that are resistant to anoikis can
reside in the liver and contribute to recurrence. Increased
invasiveness following CEACAM6 overexpression is associated
with upregulation of IGF-IR expression and MMP2 expression,
which depends upon Akt activation induced by CEACAM6
overexpression (Duxbury et al, 2004c). c-Src-dependent modula-
tion of MMP9 activity contributes significantly to the increased
cellular invasiveness induced by CEACAM6 overexpression
(Duxbury et al, 2004d). This study demonstrates that the
transfectants of the CEACAM6 gene were more proliferative in
MTT assay (Figure 4B and C), had greater invasive abilities in
matrigel assay (Figure 5A) and were more resistant to anoikis in
anoikis assay (Figure 5B) compared to mock-transfected cells,
concurring with the reports described above. Therefore, in
intrahepatic cholangiocarcinoma clinical data, these results would
be associated with lymphatic invasion and poor prognosis.
Furthermore, CEACAM6 gene silencing reversed the acquired
anoikis resistance and inhibited metastatic ability (Duxbury et al,
2004a). Suppression of CEACAM6 expression by siRNA impairs
pancreatic adenocarcinoma xenograft growth in vivo and improves
the survival of tumour-bearing nude mice (Duxbury et al, 2004b).
Blocking the N and A1B1 domains of CEACAM5/CEACAM6 can
impede the metastatic process (Blumenthal et al, 2005). Interest-
ingly, another study showed that the CEACAM6 gene was one of
the most overexpressed genes in a side population of cells of
hepatocellular carcinoma (Haraguchi et al, 2006). Most of the side
population of cells are considered to be equal to stem cells that
show strong chemoresistance to anticancer drugs. Targeting
CEACAM6 may conceivably be a therapeutic approach for patients
with cholangiocarcinoma.
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Figure 6 (A) CEACAM6 Expression of CEACAM6 suppressed cells by
CEACAM6 specific-siRNA and control cells (TFK-1). 48h after siRNA
addition, expression of CEACAM6 was measured by flow cytometry. (B)
Gemcitabine chemosensitivity of CEACAM6 suppressed cells and control
cells. 72h after gemcitabine exposure, survival rates were measured by
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gemcitabine than mock cells (Po0.01). The data represent the mean7s.d.
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most patients have advanced disease far beyond surgical
treatment. The other is that the effects of chemotherapy for
cholangiocarcinoma are largely disappointing (Kelley et al, 2004;
Olnes and Erlich, 2004; Khan et al, 2005). 5-Fluorouracil (5-FU) as
a single therapy or in combination with other drugs has been
studied extensively for cholangiocarcinoma. Although many of
these trials were small and uncontrolled, there was an overall
response rate of 0–40% and median survival of 2–12 months.
With respect to gemcitabine, response rates of 8–60% and median
overall survival of 6.3–16 months have been reported. These rates
were not changed even when gemcitabine was used in combination
with other agents (Thongprasert, 2005). Our study within
cholangiocarcinoma cell lines demonstrated that CEACAM6 over-
expressed cells were more chemoresistant to gemcitabine than
mock-transfected cells and suppression of CEACAM6 expression
by CEACAM6 siRNA increased chemosensitivity to gemcitabine.
One possible explanation of the relationship between overexpres-
sion of CEACAM6 and gemcitabine resistance is that CEACAM6
overexpression may protect cells from cytochrome c-induced
caspase 3 activation and apoptosis via Akt or c-Src activation. This
cytoprotective pathway may contribute to gemcitabine chemo-
resistance (Duxbury et al, 2004e).
In conclusion, this study provided important information that
overexpression of CEACAM6 expression may become a prognostic
marker and a chemoresistant indicator for gemcitabine in patients
with cholangiocarcinoma. CEACAM6 could play an important role
in cholangiocarcinoma. Further studies in greater numbers of
patients should lead to a final conclusion.
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